NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
GlobalData on MSN22h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacksAfter Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
Medpage Today on MSN16hOpinion
How a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback